{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:22:42Z","timestamp":1782944562967,"version":"3.54.5"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The prevalence of osteoporosis will continue to rise as the world\u2019s population ages. Since women\u2019s bones are smaller and thinner than men\u2019s, bone loss accelerates as estrogen levels fall. Based on their primary effects, drugs used to treat osteoporosis can be categorized into three groups: 1. Anti-resorptive medications. These primarily prevent osteoclasts from resorbing bone, which has a secondary effect on bone growth. Commonly used anti-resorptive drugs include bisphosphonates, denosumab, hormone replacement therapy, and raloxifene. 2. Anabolic medicines. These mainly stimulate osteoblasts to produce new bone, although they may also affect bone resorption. Common examples include teriparatide, romosozumab, and parathyroid hormone. 3. Phytoestrogens. These are non-steroidal, naturally occurring plant compounds with estrogenic and\/or anti-estrogenic properties that resemble estrogen.<\/jats:p>","DOI":"10.3389\/fmed.2025.1682333","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:32:04Z","timestamp":1763015524000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Drugs against osteoporosis in perimenopausal and postmenopausal women"],"prefix":"10.3389","volume":"12","author":[{"given":"Hong","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiucheng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston","year":"2017","journal-title":"Arch Osteoporos"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e2121106","DOI":"10.1001\/jamanetworkopen.2021.21106","article-title":"Prevalence of osteoporosis and fracturein China: the China osteoporosis prevalence study","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA NetwOpen"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jbmr.534","article-title":"Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the study of women\u2019s health across the nation (SWAN)","volume":"27","author":"Greendale","year":"2012","journal-title":"J Bone Miner Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","article-title":"Prevention and treatment of postmenopausal osteoporosis","volume":"142","author":"Tella","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1007\/s00198-024-07260-9.","article-title":"Association between renal function and fracture incidence during treatment with teriparatide or alendronate: an exploratory subgroup analysis of the Japanese osteoporosis intervention Trial-05","volume":"35","author":"Takeuchi","year":"2024","journal-title":"Osteoporos Int"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00198-019-05233-x","article-title":"Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates","volume":"31","author":"Miller","year":"2020","journal-title":"Osteoporos Int"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e0118178","DOI":"10.1371\/journal.pone.0118178","article-title":"Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study","volume":"10","author":"Real","year":"2015","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","article-title":"Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg","volume":"23","author":"Wark","year":"2012","journal-title":"Osteoporos Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e1494","DOI":"10.1210\/clinem\/dgaa933","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019; 104(5): 1623\u20131630. doi: 10.1210\/jc.2019-00192. Erratum in","volume":"106","author":"Barrionuevo","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jsbmb.2013.05.001","article-title":"Menopausal hormone therapy and risk of endometrial cancer","volume":"142","author":"Brinton","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene evaluation (MORE) investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1210\/er.2001-4002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1001\/archinte.160.22.3444","article-title":"Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials","volume":"160","author":"Johnston","year":"2000","journal-title":"Arch Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J Bone Miner Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1056\/NEJMc1714810","article-title":"Romosozumab versus alendronate and fracture risk in women with osteoporosis","volume":"378","author":"Tsourdi","year":"2018","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.tem.2005.05.002","article-title":"Black cohosh: just another phytoestrogen?","volume":"16","author":"Viereck","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.3390\/nu12123853","article-title":"Scientific evidence supporting the beneficial effects of Isoflavones on human health","volume":"12","author":"G\u00f3mez-Zorita","year":"2020","journal-title":"Nutrients"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2289S","DOI":"10.3945\/jn.110.124107","article-title":"Insights gained from 20 years of soy research","volume":"140","author":"Messina","year":"2010","journal-title":"J Nutr"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/archinternmed.2011.330","article-title":"Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial","volume":"171","author":"Levis","year":"2011","journal-title":"Arch Intern Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1375S","DOI":"10.1093\/ajcn\/68.6.1375S","article-title":"Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women","volume":"68","author":"Potter","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00198-020-05476-z","article-title":"Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Sansai","year":"2020","journal-title":"Osteoporos Int"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3945\/ajcn.116.151464","article-title":"A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women","volume":"106","author":"Lambert","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.292.1.65","article-title":"Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial","volume":"292","author":"Kreijkamp-Kaspers","year":"2004","journal-title":"JAMA"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/ajcn\/87.3.761","article-title":"Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study","volume":"87","author":"Brink","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/ph15030278","article-title":"Benefits of Black cohosh (Cimicifuga racemosa) for women health: an up-close and in-depth review","volume":"15","author":"Mohapatra","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e82815","DOI":"10.1371\/journal.pone.0082815","article-title":"Effects of remifemin treatment on bone integrity and remodeling in rats with ovariectomy-induced osteoporosis","volume":"8","author":"Cui","year":"2013","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/ptr.3624","article-title":"Evaluation of the antiosteoporotic potential of Cimicifuga heracleifolia in female mice","volume":"26","author":"Ahn","year":"2012","journal-title":"Phytother Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.fertnstert.2008.03.042","article-title":"Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line","volume":"91","author":"Garc\u00eda-P\u00e9rez","year":"2009","journal-title":"Fertil Steril"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/gme.0b013e3181cc4a00","article-title":"Effect of exercise and Cimicifuga racemosa (CR BNO 1055) on bone mineral density, 10-year coronary heart disease risk, and menopausal complaints: the randomized controlled training and Cimicifuga racemosa Erlangen (TRACE) study","volume":"17","author":"Bebenek","year":"2010","journal-title":"Menopause"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of Romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1682333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:32:04Z","timestamp":1763015524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1682333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":42,"alternative-id":["10.3389\/fmed.2025.1682333"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1682333","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"article-number":"1682333"}}